# Army Promotes CBRN OTA Collaboration

At the May 12–13 Medical CBRN Defense Consortium (MCDC) annual meeting, Army CBRN program offices described how collaboration and Other Transaction Authority (OTA) pathways can accelerate medical countermeasures and related platform technologies. The meeting signals a potential route for industry engagement, but the report identifies no specific solicitation, award, funding amount, or procurement contact.

- Contractors working on CBRN vaccines, therapeutics, diagnostics, and enabling platforms can use consortium and agency channels to identify future opportunities, as recommended in the report.
- The discussion highlights collaboration and OTA pathways as approaches the Army may use to advance medical countermeasures; it does not establish a current procurement or guarantee an award.

**Jurisdictions:** federal
**Industries:** Defense & Military, Healthcare
**Topics:** Contracting Vehicles
**Published:** October 20, 2026

### Government Entities
- Portfolio Management Executive for Chemical, Biological, Radiological and Nuclear Defense (PME CBRND)
- United States Army (Army)
- Defense Threat Reduction Agency (DTRA)
- Biomedical Advanced Research and Development Authority (BARDA)
- U.S. Food and Drug Administration (FDA)

### Key Quotes
> Our partnerships are the cornerstone of our strategy, allowing us to leverage the nation's top talent and resources to solve the military's most complex medical challenges.
> — Nicole Kilgore, PME CBRND

### Sources
- [DVIDS - News - PME CBRND Showcases Collaborative Power at MCDC Annual Meeting](https://www.dvidshub.net/news/577433/pme-cbrnd-showcases-collaborative-power-mcdc-annual-meeting) - DVIDS